Zilia Ocular to Support Study in AMD and DME
Zilia Ocular device will be used in a new 24-month clinical study at the Toronto Retina Institute (TRI). The ThRIVE study will directly compare next-generation anti-VEGF therapies in patients with age-related macular degeneration (AMD) and diabetic macular edema (DME) — two of the leading causes of vision loss worldwide.
Canadian Study on Retinal Oxygenation Using Zilia Ocular
Quebec City, February 20, 2026 – Zilia announced today that its Zilia Ocular device will be used in a new clinical study at St....
Zilia to Support Landmark Study on Retinal Degeneration and Regeneration
Quebec City, November 26, 2025 – Zilia, a health technology company at the forefront of oculomics, announced today that its...
The Eye: A Window into Cardiovascular Health | What the Retina Reveals About the Heart
The eyes have long been called the “window to the soul,” but they are also an extraordinary window into cardiovascular...
Zilia Launches Clinical Study to Investigate Ocular Oximetry as a New Glaucoma Biomarker
Quebec City, July 2, 2025 – Zilia is launching a new clinical trial in collaboration with Dr. Paul Harasymowycz, a leading...
Zilia Launches Ocular Oximetry Study for Ischemic Optic Neuropathy and Retinal Vasculitis
Quebec City, June 26, 2025 – Zilia will investigate how measuring oxygen levels in the eye could transform the diagnosis and...
Health Canada Approves Zilia Ocular
Quebec City, 19 June 2025 - Zilia, a Canadian health technology company, is proud to announce that its flagship product, the...
Zilia Reaches Milestone of 1,000 Patients Enrolled in Clinical Studies
Quebec City, January 14, 2025 – Zilia has reached a significant milestone with over 1,000 patients now enrolled in clinical...
Oculomics: Non-Invasive Insights into Overall Health
While it's often said that the eyes are windows to the soul, they are equally profound windows to our health.The unique...
Zilia Launches Innovative Project to Detect a Rare Heart Disease
Quebec City, 15 May 2024 - Zilia, a Quebec-based medical technology company, announces the launch of a pilot study in...
Zilia Partners with Kagawa University for Groundbreaking Retinal Oxygenation Study in Japan
Quebec City, Apr. 30, 2024 - Zilia, a pioneer in non-invasive ocular biomarker technologies, announces a collaboration with...
Oxygen’s Complex Role in Retinopathy of Prematurity
Premature birth is a remarkable feat of medicine. However, this early entrance into the world can sometimes lead to unforeseen...
Oxidative Stress and Eye Health
Oxygen plays an important role in our universe, being the third most abundant element and the second most abundant in the...
Spectroscopy: From the Stars to the Eyes
The James Webb Space Telescope is the result of an international collaborative effort to solve mysteries in our solar system...
University of Houston Presents First Abstract on Ocular Oximetry
Diabetes is projected to affect 640 million adults worldwide by 2040. Diabetic retinopathy (DR), a retinal disease affecting 1...
The Eye as a Window to AI in Healthcare
The term Artificial Intelligence (AI) was first coined by John McCarthy in 1956 when he defined the concept as “the science and...
Zilia Receives ISO 13485:2016 Certification
Zilia has received certification from Intertek that its quality management system meets the ISO 13485 : 2016 standard for...
Impact of Vision Loss on Quality of Life
We experience the world using our five senses: sight, smell, taste, hearing, and touch. But which one is most important to our...
Ocular Oximetry: A Paradigm Shift in Retinal Vein Occlusion Management?
Retinal vein occlusion (RVO) affects more than 1.1 million people in the U.S. and is considered to be an important cause of...
Diabetic Retinopathy: A Key Role for Ocular Oximetry?
Diabetic retinopathy (DR), the most common complication of diabetes, is a retinal disease, characterized by ischemia,...
Zilia appoints Étienne Lagacé to its Board of Directors
Zilia is delighted to announce the appointment of Étienne Lagacé to its Board of Directors.For the last two decades, Étienne has...
Solutions
